血小板減少性疾病：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 法國血小板減少性疾病市場預計將從 2025 年的 9,500 萬美元成長到 2035 年的 1.6 億美元。
• 推動市場成長的因素如下：
• 擴大血小板生成素促效劑和標靶治療的應用
• 改善慢性血小板減少性疾病的診斷和治療
• 未來的成長取決於能夠提供持續血小板反應並降低出血風險的療法。

血小板減少性疾病的新療法及對TPP的深入了解

Thelansis 的《血小板減少性疾病：新型療法、未滿足的需求和 TPP 洞察報告，2026》對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

血小板減少性疾病概述

血小板減少性疾病是指血小板數量下降，原因包括骨髓生成受損、免疫或非免疫性破壞增加、消耗、稀釋或脾臟滯留。臨床意義因病因而異，取決於病因和嚴重程度。重度血小板減少性疾病可引起瘀點、黏膜出血或出血。治療方法因病因而異，包括治療感染疾病或藥物誘發因子、使用皮質類固醇或免疫球蛋白治療免疫性血小板減少性疾病症、輸注血小板治療某些出血性疾病以及治療潛在的骨髓或全身性疾病。血小板生成素受體促效劑，如羅米前列素、艾曲波帕和阿伐曲波帕，是治療慢性免疫性血小板減少性疾病症的常用藥物，在某些情況下也可用於治療其他疾病，但它們並非血小板減少性疾病的萬靈藥。研發工作正不斷拓展，旨在改善血小板生成、免疫調節以及治療化療引起的血小板減少性疾病。關鍵需求包括持續的療效和更安全的標靶治療。

主要亮點

• 根據預測，德國血小板減少性疾病患者人數將從 2025 年的 145,075 人增加到 2035 年的 148,284 人。
• 血小板減少性疾病的特徵是血小板數量減少，這會增加出血和相關併發症的風險。
• 這種疾病的負擔仍然很重，尤其是在患有慢性或治療引起的血小板減少性疾病的患者中。
• 目前仍有大量未被滿足的需求，即開發既能提高安全性又能持續恢復血小板計數的治療方法。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期及其他預測
• 臨床試驗現況分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 特徵和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion SpA
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Thrombocytopenia Emerging Therapy and TPP Insights

Thelansis's "Thrombocytopenia Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Thrombocytopenia Overview

Thrombocytopenia is a reduction in platelet count that can arise from impaired marrow production, increased immune or nonimmune destruction, consumption, dilution, or splenic sequestration. Clinical significance varies with cause and severity; severe thrombocytopenia can cause petechiae, mucosal bleeding, or hemorrhage. Management is cause-specific and may include treating infection or drug triggers, corticosteroids or immunoglobulin for immune thrombocytopenia, platelet transfusion for selected bleeding settings, and therapy for underlying marrow or systemic disorders. Thrombopoietin receptor agonists, including romiplostim, eltrombopag, and avatrombopag, are established options in chronic immune thrombocytopenia and selected settings, but are not universal treatments for thrombocytopenia. Development is expanding toward improved platelet production, immune modulation, and therapies for chemotherapy-induced thrombocytopenia. Key needs include durable responses and safer targeted care.

Key Highlights

• In Germany, the prevalent Thrombocytopenia population is projected to increase from 145,075 in 2025 to 148,284 by 2035.
• Thrombocytopenia is characterized by low platelet counts, increasing the risk of bleeding and associated complications.
• Disease burden remains significant, particularly in patients with chronic or treatment-induced thrombocytopenia.
• Significant unmet need remains for therapies that provide sustained platelet recovery with improved safety.

Market Overview

• The France Thrombocytopenia market is projected to grow from $95M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing adoption of thrombopoietin receptor agonists and targeted therapies
• Improved diagnosis and management of chronic thrombocytopenia
• Future growth will depend on therapies that offer durable platelet response and reduced bleeding risk.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion S.p.A.
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)